Reply to: Renal impairment during the treatment of telaprevir with peginterferon and ribavirin in patients with chronic hepatitis C
[ X ]
Tarih
2014
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Blackwell Publishing Ltd
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Dear Editor, We read with great interest the recently published article by Fukuda et al. 1 The authors indicate that there is significant correlation between serum telaprevir (TVR) level and bodyweight and suggest that adjustment of TVR dose according to bodyweight would avoid renal impairment during treatment. Herein, we want to present a case in which renal impairment completely reversed after discontinuation of TVR, and ribavirin dose reduction seemed to be important in improving renal impairment until therapy.
Açıklama
Anahtar Kelimeler
[Belirlenecek]
Kaynak
Hepatology Research
WoS Q Değeri
N/A
Scopus Q Değeri
Q1
Cilt
44
Sayı
9
Künye
Sakin, Y. S., Polat, Z., Demirci, H., Kekilli, M., Uygun, A., Bağcı, S. (2014). Reply to: Renal impairment during the treatment of telaprevir with peginterferon and ribavirin in patients with chronic hepatitis C. Hepatology Research, 44(9), 1037-1037.
